Dupixent access in the UAE: the EDE named-patient pathway
How UAE patients legally obtain Dupixent (dupilumab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Dupixent (dupilumab) is an interleukin-4 receptor alpha blocker approved by the US FDA across six type 2 inflammatory indications: atopic dermatitis from 6 months of age and up, moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis in patients 1 year and older, prurigo nodularis, and COPD with type 2 inflammation. The drug is locally registered in the UAE through MOHAP and DHA channels for the principal indications. Even so, UAE families regularly use the federal named-patient pathway to bridge gaps that local registration alone does not close: an under-6 pediatric atopic dermatitis case, a weight-banded pen presentation that is not stocked at the local agent, a payer denial on the asthma or EoE indication, or a COPD case where the 2024 US label has not yet translated into local reimbursement. Reserve Meds coordinates the US-side sourcing, the cold-chain logistics, and the documentation packet your physician needs.
Reserved for you.
Why UAE patients need Dupixent through the named-patient pathway
The United Arab Emirates operates one of the most developed pharmaceutical regulatory environments in the Gulf Cooperation Council. As of 29 December 2025, under Federal Decree-Law No. 38 of 2024, the newly established Emirates Drug Establishment (EDE) assumed 44 core services from MOHAP, including marketing authorisations and personal-use import permits. Dupixent is on the federal register, and a UAE family asking for Dupixent is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Newer Dupixent indications, especially pediatric atopic dermatitis under 6 years, pediatric EoE under 12 years, prurigo nodularis, and COPD with type 2 inflammation, often reach local registration 12 to 36 months after FDA approval. A family with a 3-year-old whose dermatologist has documented severe atopic dermatitis fits the US label but may not fit the current UAE label. Second, weight-banded pen presentations. A 25 kg child needing the 200 mg pen may find only the 300 mg pen on local shelves; the local agent may not carry every weight band reliably. Third, payer denial. Daman, GIG Gulf (formerly AXA Gulf), Sukoon (formerly Oman Insurance Company), ADNIC, and Orient each assess specialty biologics case by case, and type 2 inflammation indications often fail step-therapy or formulary coverage even when the drug is registered. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, brand familiarity. Heavy US direct-to-consumer advertising has built strong patient awareness across MENA, and families arrive asking for Dupixent by brand name.
In each pattern, the named-patient pathway is the mechanism that connects a UAE-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient.
The EDE named-patient pathway for Dupixent
The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, historically administered by MOHAP and, from 29 December 2025, administered through the EDE portal at ede.gov.ae. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. For Dupixent specifically, the clinical justification typically frames the case around the precise FDA-approved indication and the documented gap in the local route.
A complete application includes a clinical justification letter from the treating physician (diagnosis, severity, prior therapies, why this specific drug, why the locally stocked option is not suitable for this case), the treating physician's UAE medical license verification (MOHAP, DHA, DOH, or Sharjah Health Authority, depending on practice location), an anonymised patient identifier where the EDE submission allows, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity requested, intended treatment duration), the destination dispensing facility name, license number, and pharmacy in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy, including cold-chain handling.
For Dupixent, the clinical justification angle typically rests on one of three documented elements. For a pediatric atopic dermatitis case under 6 years, the prescriber documents the FDA-approved age indication and the local indication gap. For a denied biologic claim on asthma, EoE, or COPD, the prescriber documents prior step-therapy failure and the type 2 inflammation phenotype (eosinophil count, IgE level, or biopsy finding where relevant). For a weight-banded pen request, the prescriber specifies the exact 100 mg, 150 mg, 200 mg, or 300 mg presentation required and the weight band that drives the choice.
Approval timelines for routine cases are typically 5 to 15 business days. Complex cases (rare indication, larger quantities, first import of a given pediatric pen format) can extend to 4 to 6 weeks. The EDE retains discretion on timing, and we do not promise specific durations.
Where Dupixent gets dispensed in the UAE
A small group of UAE institutions handle named-patient imports as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. For cold-chain biologics like Dupixent, the dispensing facility must maintain 2 to 8 degrees Celsius storage with continuous monitoring. Tertiary and major private hospitals that meet this profile include Cleveland Clinic Abu Dhabi on Al Maryah Island (an M42 group hospital with ASHP-accredited pharmacy services), Sheikh Khalifa Medical City in Abu Dhabi (a SEHA-network 586-bed JCI-accredited hospital), Tawam Hospital in Al Ain (a SEHA-network referral center with pediatric services), American Hospital Dubai (a Mayo Clinic Care Network member with strong dermatology and pulmonology services), King's College Hospital London Dubai, Mediclinic City Hospital in Dubai Healthcare City, and the larger NMC Healthcare sites across Abu Dhabi, Dubai, Sharjah, and Al Ain.
For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a Dubai- or Abu Dhabi-based specialty importer that holds a pharmaceutical establishment license and files the EDE application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient pharmacy under chain-of-custody documentation.
Real cost picture for Dupixent in the UAE
US WAC for Dupixent is approximately USD 3,993 per 300 mg pen carton (two-pack) as disclosed by Sanofi in January 2025, which translates to an annual WAC in the range of USD 37,000 to USD 43,000 for the most common adult atopic dermatitis regimen (300 mg every 2 weeks, 26 doses per year). The UAE dirham is pegged to the US dollar at approximately 3.67 AED to 1 USD, so the annual reference range converts to roughly AED 136,000 to AED 158,000 for the drug itself at US WAC equivalents.
International logistics for a cold-chain biologic shipment to the UAE typically runs USD 400 to USD 1,500 (approximately AED 1,500 to AED 5,500) depending on destination emirate, urgency, and pen-format pack size. UAE customs and EDE permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the insurance side, each UAE insurer assesses named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. Thiqa, the government-funded programme for UAE nationals administered by Daman, has the broadest specialty coverage in Abu Dhabi. We do not promise coverage from any insurer. The DUPIXENT MyWay copay card and US manufacturer patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage.
Typical timeline for Dupixent in the UAE
EDE routine processing is typically 5 to 15 business days from a complete filing. For Dupixent specifically, cold-chain shipment adds 2 to 3 days versus an ambient small molecule because validated thermal packaging, continuous temperature monitoring, and customs clearance scheduled to avoid tarmac heat exposure are non-negotiable. End-to-end, most adult atopic dermatitis or asthma cases complete within 3 to 5 weeks from first complete documentation. Pediatric weight-banded cases may run slightly longer because pen-format selection and first-import scrutiny can extend EDE review. The 14-day room-temperature excursion runway on the FDA label gives meaningful operational flexibility for the Gulf shipping lane, provided the cold chain is properly broken only at the dispensing pharmacy.
What your physician needs to provide
For a UAE-licensed dermatologist, pulmonologist, allergist, gastroenterologist, or pediatric specialist prescribing Dupixent through the EDE pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis (atopic dermatitis with severity score, asthma with eosinophilic phenotype documented by blood eosinophil count, CRSwNP, EoE with biopsy confirmation, prurigo nodularis, or COPD with type 2 inflammation), prior therapy history including topical or systemic corticosteroids, prior biologics tried where relevant, and a clinical rationale for why dupilumab is the appropriate next step.
The letter also specifies the exact dosing plan per the FDA-approved label: 600 mg load then 300 mg every 2 weeks for adult atopic dermatitis, weight-banded dosing for pediatric atopic dermatitis (200 mg or 300 mg every 4 weeks below 30 kg; 200 mg every 2 weeks for 30 to 60 kg), the asthma-specific regimen for moderate-to-severe asthma, 300 mg every 2 weeks for CRSwNP and COPD, and the weekly or every-other-week EoE schedule depending on age and weight. Monitoring plan should reference helminth-infection assessment at baseline for patients from endemic regions, ophthalmology follow-up where conjunctivitis is a concern, and continuation of any background topical or inhaled therapy until the prescriber adjusts it.
For asthma specifically, the physician documents TB screening or status as part of the broader workup for any biologic patient with respiratory comorbidity, in line with general UAE practice for immunomodulator initiation. The treating physician's UAE license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package.
Common questions about Dupixent in the UAE
Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Dupixent is on their formulary even if not currently stocked. Thiqa has the broadest specialty coverage in Abu Dhabi for UAE nationals. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
My child is 4 years old. Is the under-6 indication covered? The FDA approved Dupixent for atopic dermatitis in infants and young children 6 months and older in June 2022. The local UAE indication may lag the FDA timeline; the EDE pathway exists precisely to bridge this gap when the local label has not caught up.
My physician is DHA-licensed and the hospital is in Dubai. Is that fine? Yes. Any UAE-licensed physician practicing in good standing in the emirate of the dispensing facility has signing authority on the clinical justification letter. DHA, MOHAP, DOH, and Sharjah Health Authority all participate in the EDE workflow through their respective jurisdictions.
What about TB screening for the asthma indication? Dupixent itself does not carry a TB screening requirement in its FDA label, in contrast to anti-TNF agents and JAK inhibitors. The patient's pulmonologist may still order baseline TB workup as part of standard moderate-to-severe asthma assessment, particularly where comorbidities or epidemiological risk warrant it. This is a clinical decision, not a label requirement.
What about competitors like Adbry or Ebglyss? In atopic dermatitis, tralokinumab (Adbry) and lebrikizumab (Ebglyss) are alternative IL-13 pathway biologics, and JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib are oral alternatives. In asthma, omalizumab, mepolizumab, reslizumab, benralizumab, and tezepelumab sit in the same competitive set. Choice depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed.
Can I receive Dupixent at home? The dispensing facility must be UAE-licensed. The hospital outpatient pharmacy releases the pen to you after final verification, and you then administer the subcutaneous injection at home after training. The cold-chain handoff ends at the dispensing pharmacy; home refrigeration and injection-site rotation are part of your patient onboarding kit.
Where Reserve Meds fits in Dupixent cases
Reserve Meds is a US-based concierge coordinator. We do not replace your dermatologist, allergist, pulmonologist, or pediatrician, we do not replace the EDE, and we do not replace your dispensing pharmacy. For Dupixent specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the UAE, and assign a single named coordinator through the case. No prior Reserve Meds case experience for Dupixent is logged yet; standard NPP coordination under our cold-chain biologic playbook applies. Pediatric pen selection, weight-banded dosing confirmation, and home-injection education are the recurring operational fundamentals we expect for this drug.
Next step
If your UAE physician has prescribed Dupixent and you are weighing the cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.